MA35414B1 - Formulations de vaccin parenteral contre un norovirus - Google Patents
Formulations de vaccin parenteral contre un norovirusInfo
- Publication number
- MA35414B1 MA35414B1 MA36741A MA36741A MA35414B1 MA 35414 B1 MA35414 B1 MA 35414B1 MA 36741 A MA36741 A MA 36741A MA 36741 A MA36741 A MA 36741A MA 35414 B1 MA35414 B1 MA 35414B1
- Authority
- MA
- Morocco
- Prior art keywords
- norovirus
- vaccine formulations
- parenteral vaccine
- formulations against
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions de vaccin parentéral, à dose unique, qui comportent des mélanges de particules de type virus norovirus monovalent. L'invention concerne également des procédés pour conférer une immunité protectrice contre des infections par le norovirus à un sujet humain par l'administration de telles compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506447P | 2011-07-11 | 2011-07-11 | |
PCT/US2012/046222 WO2013009849A1 (fr) | 2011-07-11 | 2012-07-11 | Formulations de vaccin parentéral contre un norovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35414B1 true MA35414B1 (fr) | 2014-09-01 |
Family
ID=47506489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36741A MA35414B1 (fr) | 2011-07-11 | 2014-02-06 | Formulations de vaccin parenteral contre un norovirus |
Country Status (29)
Country | Link |
---|---|
US (5) | US9801934B2 (fr) |
EP (3) | EP3299030B1 (fr) |
JP (2) | JP6208659B2 (fr) |
KR (1) | KR102096937B1 (fr) |
CN (3) | CN103874507A (fr) |
AU (2) | AU2012282658B2 (fr) |
BR (1) | BR112014000656A2 (fr) |
CA (1) | CA2841356C (fr) |
CL (1) | CL2014000082A1 (fr) |
CR (2) | CR20190540A (fr) |
DK (1) | DK3299030T3 (fr) |
DO (2) | DOP2014000004A (fr) |
EA (3) | EA035442B1 (fr) |
EC (1) | ECSP14013201A (fr) |
ES (2) | ES2926487T3 (fr) |
GE (1) | GEP201706668B (fr) |
HK (3) | HK1198136A1 (fr) |
IL (1) | IL230356B (fr) |
MA (1) | MA35414B1 (fr) |
MX (1) | MX356586B (fr) |
MY (1) | MY170746A (fr) |
PE (1) | PE20140845A1 (fr) |
PH (1) | PH12018501515A1 (fr) |
PL (2) | PL3299030T3 (fr) |
SG (1) | SG10201605644WA (fr) |
TN (1) | TN2014000008A1 (fr) |
UA (1) | UA117732C2 (fr) |
WO (1) | WO2013009849A1 (fr) |
ZA (2) | ZA201401012B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2601969B1 (fr) | 2006-09-29 | 2016-03-30 | Takeda Vaccines, Inc. | Formulations de vaccin contre un norovirus |
JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
PL3299030T3 (pl) | 2011-07-11 | 2022-12-05 | Takeda Vaccines, Inc. | Pozajelitowe preparaty szczepionek przeciw norowirusowi |
JP2016533172A (ja) | 2013-10-03 | 2016-10-27 | タケダ ワクチン,インコーポレイテッド | 細胞株からラブドウイルスを検出および除去する方法 |
WO2015093452A1 (fr) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | Microaiguille |
CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
GB201703644D0 (en) | 2017-03-07 | 2017-04-19 | Elopak As | Improvements in or relating to toller mounting arrangements |
US11306292B2 (en) * | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3752185A1 (fr) | 2018-02-15 | 2020-12-23 | Icon Genetics GmbH | Composition immunogène et vaccin pour générer une réponse immunitaire à un norovirus |
WO2019231712A1 (fr) * | 2018-05-29 | 2019-12-05 | Stc.Unm | Compositions de particules de type viral et leurs procédés d'utilisation |
CN109265542B (zh) * | 2018-09-27 | 2021-06-15 | 国药中生生物技术研究院有限公司 | 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用 |
AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
US20230285534A1 (en) | 2020-01-08 | 2023-09-14 | Bharat Biotech International Limited | Viral vaccine compositions and methods of preparations thereof |
JPWO2022210742A1 (fr) | 2021-03-29 | 2022-10-06 | ||
US20240238401A1 (en) | 2021-05-21 | 2024-07-18 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
CN118252924A (zh) * | 2022-12-27 | 2024-06-28 | 远大赛威信生命科学(南京)有限公司 | 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
AU1893592A (en) | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
CA2133339A1 (fr) | 1992-04-08 | 1993-10-09 | Jennifer S. Rota | Glycoproteines du virus morbilleux sauvage : vaccin et methode de depistage |
JPH08500250A (ja) | 1992-09-07 | 1996-01-16 | ベイラー・カレッジ・オブ・メディシン | ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬 |
WO1994021292A1 (fr) | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle |
US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
CA2189882C (fr) | 1994-05-16 | 2005-09-20 | Kathrin U. Jansen | Vaccins contre le papillomavirus |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US5834015A (en) * | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
PL336715A1 (en) | 1997-04-08 | 2000-07-03 | Merck & Co Inc | Stabilised formulation of human papilloma virus |
AU750702B2 (en) | 1997-05-01 | 2002-07-25 | Chiron Corporation | Use of virus-like particles as adjuvants |
US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
SK2232001A3 (en) | 1998-08-14 | 2001-08-06 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
AU770809B2 (en) | 1998-12-17 | 2004-03-04 | Merck Sharp & Dohme Corp. | Synthetic virus-like particles with heterologous epitopes |
EP1150712B1 (fr) | 1999-02-05 | 2008-11-05 | Merck & Co., Inc. | Formulations vaccinales contre le virus du papillome humain |
KR100771402B1 (ko) | 1999-06-22 | 2007-10-30 | 국립감염증연구소장이 대표하는 일본국 | Srsv 검출 킷트 |
JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス(nv)を認識するモノクローナル抗体 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
US20040121465A1 (en) | 2002-02-14 | 2004-06-24 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
CA2482448C (fr) | 2002-04-11 | 2014-07-08 | Medimmune Vaccines, Inc. | Conservation de matieres bio-actives au moyen de mousse lyophilisee |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
WO2003103605A2 (fr) | 2002-06-07 | 2003-12-18 | Large Scale Biology Corporation | Ensemble de vaccins adaptable et plate-forme d'administration de vaccins |
US20040005338A1 (en) | 2002-06-20 | 2004-01-08 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
CA2514667C (fr) | 2003-01-30 | 2013-01-08 | Chiron Corporation | Vaccin contre la grippe contenant un adjuvant |
EP1599188A2 (fr) | 2003-02-20 | 2005-11-30 | Becton, Dickinson and Company | FORMULATIONS EN POUDRE DE L'ENTROTOXINE STAPHYLOCOCCIQUE B (<SB>R</SB>SEB) PRODUIT PAR SECHAGE PAR PULVERISATION POUR UNE VACCINATION AMELIOREE |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
EP1670824A2 (fr) | 2003-09-24 | 2006-06-21 | Montana State University | Anticorps monoclonaux de norovirus et peptides |
US7795242B2 (en) | 2003-10-15 | 2010-09-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
EA015907B1 (ru) | 2004-10-20 | 2011-12-30 | Санофи Пастер Байолоджикс Ко. | Рекомбинантный флавивирус и его применение |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
RU2007129840A (ru) | 2005-01-05 | 2009-02-20 | Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) | Средства доставки, биологически активные вещества и вирусные вакцины |
EP1846439A2 (fr) | 2005-01-31 | 2007-10-24 | The Johns Hopkins University | Utilisation de sequences consensus en tant qu'antigene de vaccin dans le but d'ameliorer la reconnaissance de variants viraux virulents |
CN101180312A (zh) | 2005-02-18 | 2008-05-14 | 诺华疫苗和诊断公司 | 来自尿路病原性大肠杆菌的免疫原 |
DK1868642T3 (da) | 2005-03-18 | 2013-06-24 | Cytos Biotechnology Ag | Katte-allergenfusionsproteiner og anvendelser deraf |
EP1885394A4 (fr) | 2005-06-01 | 2009-10-21 | Dow Global Technologies Inc | Production de particules multivalentes semblables à des virus |
EP1736538A1 (fr) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Procédé pour la purification préparative de particules pseudo-virales (VLPs) |
JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスgiの高感度検出方法 |
US20080029915A1 (en) * | 2006-08-02 | 2008-02-07 | Courtoy Nv | Rotary tablet press |
EP2601969B1 (fr) * | 2006-09-29 | 2016-03-30 | Takeda Vaccines, Inc. | Formulations de vaccin contre un norovirus |
ES2480491T3 (es) | 2006-12-06 | 2014-07-28 | Novartis Ag | Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe |
HUE028605T2 (en) * | 2007-03-14 | 2016-12-28 | Takeda Vaccines Inc | Cleaning virus-like particles |
AU2008299589B2 (en) | 2007-09-12 | 2014-06-26 | Australian Centre For Plant Functional Genomics Pty Ltd | Plant seed active transcriptional control sequences |
US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
EP3382011A1 (fr) | 2008-08-08 | 2018-10-03 | Takeda Vaccines, Inc. | Particules de type virus comprenant des séquences d'acides aminés de capside composites pour une réactivité croisée améliorée |
JP2012515752A (ja) * | 2009-01-22 | 2012-07-12 | ファーマシーネ,インコーポレイテッド | 安定なワクチン組成物とその使用方法 |
EP2942062A1 (fr) * | 2009-02-10 | 2015-11-11 | Novartis AG | Posologies de vaccin antigrippal pour souches liées à une pandémie |
US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
WO2011091279A2 (fr) * | 2010-01-21 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Présentation d'antigènes hétérologues ciblés sur des pseudo-particules virales du calicivirus |
KR20130108983A (ko) * | 2010-05-26 | 2013-10-07 | 셀렉타 바이오사이언시즈, 인크. | 커플링되지 않은 애주번트를 갖는 나노담체 조성물 |
PL3299030T3 (pl) | 2011-07-11 | 2022-12-05 | Takeda Vaccines, Inc. | Pozajelitowe preparaty szczepionek przeciw norowirusowi |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
US10975149B2 (en) | 2015-12-16 | 2021-04-13 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced SH2 protein in NK cells |
JP7181862B2 (ja) | 2016-10-18 | 2022-12-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 腫瘍浸潤リンパ球および治療の方法 |
JP2021522798A (ja) | 2018-05-03 | 2021-09-02 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
WO2020041192A1 (fr) | 2018-08-20 | 2020-02-27 | Takeda Vaccines, Inc. | Formulations de ppv |
AR117462A1 (es) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
MX2021009742A (es) | 2019-02-15 | 2021-12-10 | Editas Medicine Inc | Celulas asesinas naturales (nk) modificadas para inmunoterapia. |
-
2012
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/pl unknown
- 2012-07-11 CR CR20190540A patent/CR20190540A/es unknown
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/da active
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/fr active Active
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/zh active Pending
- 2012-07-11 CA CA2841356A patent/CA2841356C/fr active Active
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/fr active Active
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/pt not_active Application Discontinuation
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/ja active Active
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 EA EA201792407A patent/EA035442B1/ru not_active IP Right Cessation
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 PL PL12811916T patent/PL2731621T3/pl unknown
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/zh active Pending
- 2012-07-11 EA EA201490258A patent/EA029470B1/ru not_active IP Right Cessation
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/ko active IP Right Grant
- 2012-07-11 EA EA202090699A patent/EA202090699A3/ru unknown
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/zh active Pending
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/fr active Pending
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/es active IP Right Grant
- 2012-07-11 MX MX2014000411A patent/MX356586B/es active IP Right Grant
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/fr active Application Filing
- 2012-07-11 ES ES17199372T patent/ES2926487T3/es active Active
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/es active Active
- 2012-11-07 UA UAA201401321A patent/UA117732C2/uk unknown
-
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
-
2014
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/es unknown
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/es unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/fr unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/es unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/es unknown
- 2014-11-21 HK HK14111772.5A patent/HK1198136A1/xx unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/zh unknown
- 2014-12-18 HK HK14112697.5A patent/HK1199202A1/xx unknown
-
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
-
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/ja active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
-
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515A1/en unknown
-
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
-
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/es unknown
-
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35414B1 (fr) | Formulations de vaccin parenteral contre un norovirus | |
EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
PH12015501156A1 (en) | Pharmaceutical compositions | |
MD20140136A2 (ro) | Inhibitori ai virusului hepatic C | |
MD20200093A2 (ro) | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică | |
NZ721952A (en) | Delayed release compositions of linaclotide | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
MY168959A (en) | Vaccine compositions for the prevention of dengue virus infection | |
PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
AR061894A1 (es) | Vacunas para malaria | |
WO2012075362A3 (fr) | Modulateurs du récepteur cxcr4 de la chimiokine et leurs utilisations | |
WO2014205199A3 (fr) | Compositions et méthodes de potentialisation de la réponse immunitaire, de stimulation de l'immunothérapie et d'augmentation de la puissance d'un vaccin | |
EA201490222A1 (ru) | Комбинированные составы на основе дарунавира | |
EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с | |
MD20140094A2 (ro) | Spiro [2.4]heptani pentru tratamentul infecţiilor cauzate de Flaviviridae | |
EA201490223A1 (ru) | Составы на основе дарунавира | |
UA118542C2 (uk) | Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197 | |
EA201590678A1 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
MX364946B (es) | Sistema adyuvante mejorado para la administración de vacunas orales. | |
MA35303B1 (fr) | Vaccin contre la rhinite equine | |
IN2013MU01177A (fr) | ||
EA032913B1 (ru) | Препараты производных пиримидиндиона |